Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4–5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial

The Lancet Gastroenterology and Hepatology

Volumn 2, Issue 8, 2017, Pages 585-594

  Bruchfeld, Annette ^a   Roth, David ^b   Martin, Paul ^b   Nelson, David R ^c   Pol, Stanislas ^d   Londoño, Maria Carlota ^e   Monsour, Howard ^f   Silva, Marcelo ^g   Hwang, Peggy ^h   Arduino, Jean Marie ^h   Robertson, Michael ^h   Nguyen, Bach Yen ^h   Wahl, Janice ^h   Barr, Eliav ^h   Greaves, Wayne ^h  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d Institut Cochin   (France)

^e INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^f HOUSTON METHODIST HOSPITAL   (United States)

^g UNIVERSIDAD AUSTRAL   (Argentina)

^h MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; ELBASVIR PLUS GRAZOPREVIR; NONSTRUCTURAL PROTEIN 5A; PLACEBO; 2-(PYRROLIDIN-2-YL)-5-(2-(4-(5-(PYRROLIDIN-2-YL)-1H-IMIDAZOL-2-YL)PHENYL)BENZOFURAN-5-YL)-1H-IMIDAZOLE; ANTIVIRUS AGENT; BENZOFURAN DERIVATIVE; IMIDAZOLE DERIVATIVE; MK-5172; QUINOXALINE DERIVATIVE;

ADULT; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DEATH; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HEMODIALYSIS; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; INSOMNIA; INTERSTITIAL NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEIZURE; SHORT FORM 36; TREATMENT OUTCOME; VIRUS RESISTANCE; ANTIVIRAL RESISTANCE; CHRONIC HEPATITIS C; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; DRUG ADMINISTRATION; DRUG EFFECT; GENETICS; GENOTYPE; HEPACIVIRUS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SUSTAINED VIROLOGIC RESPONSE; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; BENZOFURANS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PATIENT OUTCOME ASSESSMENT; QUALITY OF LIFE; QUINOXALINES; RENAL INSUFFICIENCY, CHRONIC; SUSTAINED VIROLOGIC RESPONSE;

EID: 85021762048     PISSN: 24681253     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2468-1253(17)30116-4     Document Type: Article

References (34)

1. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62 (2015), 932–954.
2. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol 66 (2017), 153–194.
3. Jadoul, M, Bieber, B, Goodkin, DA, et al. Hepatitis C infection in hemodialysis patients is associated with inferior quality of life in the DOPPS. Nephrol Dial Transplant, 30(suppl 3), 2015, iii307.
4. Fabrizi, F, Dixit, V, Messa, P, Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality?. J Viral Hepat 19 (2012), 601–607.
5. Fabrizi, F, Martin, P, Dixit, V, Bunnapradist, S, Kanwal, F, Dulai, G, Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies. Am J Transplant 5 (2005), 2433–2440.
6. Cruzado, JM, Carrera, M, Torras, J, Grinyó, JM, Hepatitis C virus infection and de novo glomerular lesions in renal allografts. Am J Transplant 1 (2001), 171–178.
7. Bruchfeld, A, Wilczek, H, Elinder, C-G, Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation. Transplantation 78 (2004), 745–750.
8. Molnar, MZ, Alhourani, HM, Wall, BM, et al. Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans. Hepatology 61 (2015), 1495–1502.
9. Roth, D, Nelson, DR, Bruchfeld, A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 386 (2015), 1537–1545.
10. Zeuzem, S, Ghalib, R, Reddy, KR, et al. Grazoprevir–elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 163 (2015), 1–13.
11. Rockstroh, JK, Nelson, M, Katlama, C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV 2 (2015), e319–e327.
12. Forns, X, Gordon, SC, Zuckerman, E, et al. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J Hepatol 63 (2015), 564–572.
13. Buti, M, Gordon, SC, Zuckerman, E, et al. Grazoprevir, elbasvir, and ribavirin for chronic hepatitis C virus genotype 1 infection after failure of pegylated interferon and ribavirin with an earlier-generation protease inhibitor: final 24-week results from C-SALVAGE. Clin Infect Dis 62 (2016), 32–36.
14. Zepatier package insert, 2016, Merck & Co, Whitehouse Station, NJ.
15. Foucher, J, Chanteloup, E, Vergniol, J, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 55 (2006), 403–408.
16. Castera, L, Forns, X, Alberti, A, Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 48 (2008), 835–847.
17. Boursier, J, de Ledinghen, V, Zarski, J-P, et al., multicentre groups from SNIFF 32, VINDIAG 7, and ANRS/HC/EP23 FIBROSTAR studies. Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive. Hepatology 55 (2012), 58–67.
18. Maruish, ME, User's manual for the SF-36v2 Health Survey, 3rd edn, 2011, QualityMetric Incorporated, Lincoln, RI.
19. Spiegel, BMR, Younossi, ZM, Hays, RD, et al. Impact of hepatitis C on health-related quality of life: a systematic review and quantitative assessment. Hepatology 41 (2005), 790–800.
20. Cohen, J, Statistical power analysis for the behavioral sciences, 2nd edn., 1988, Lawrence Erlbaum Associates, Hillsdale, NJ.
21. Foster, GR, Quality of life considerations for patients with chronic hepatitis C. J Viral Hepatol 16 (2009), 605–611.
22. Soni, RK, Weisbord, SD, Unruh, ML, Health-related quality of life outcomes in chronic kidney disease. Curr Opin Nephrol Hypertens 19 (2010), 153–159.
23. Avramovic, M, Stefanovic, V, Health-related quality of life in different stages of renal failure. Artif Organs 36 (2012), 581–589.
24. Younossi, Z, Henry, L, Systematic review: patient-reported outcomes in chronic hepatitis C—the impact of liver disease and new treatment regimens. Aliment Pharmacol Ther 41 (2015), 497–520.
25. Bruchfeld, A, Lindahl, K, Reichard, O, Carlsson, T, Schvarcz, R, Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat 13 (2006), 316–321.
26. Younossi, ZM, Stepanova, M, Sulkowski, M, Naggie, S, Henry, L, Hunt, S, Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus. J Viral Hepat 23 (2016), 857–865.
27. Younossi, ZM, Stepanova, M, Feld, J, et al. Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: results from ASTRAL-1 placebo-controlled trial. J Hepatol 65 (2016), 33–39.
28. Younossi, ZM, Stepanova, M, Marcellin, P, et al. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1, -2, and -3 clinical trials. Hepatology 61 (2015), 1798–1808.
29. Pockros, PJ, Reddy, KR, Mantry, PS, et al. Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology 150 (2016), 1590–1598.
30. Sovaldi package insert, 2015, Gilead Sciences, Foster City, CA.
31. Desnoyer, A, Pospai, D, Lê, MP, et al. Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. J Hepatol 65 (2016), 40–47.
32. Rosenblatt R, Mehta A, Wagner M, Kumar S. Baseline creatinine clearance is a predictor of worsening renal function while on HCV treatment with sofosbuvir-ledipasvir. The International Liver Congress; April 13–17, 2016; Barcelona, Spain.
33. Saxena, V, Koraishy, FM, Sise, ME, et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int 36 (2016), 807–816.
34. Epclusa (package insert), 2016, Gilead Sciences, Foster City, CA.